0A4Y 주식 개요 면역 제약 회사인 AIM ImmunoTech는 미국에서 여러 유형의 암, 바이러스 질환, 면역 결핍 장애를 치료하는 치료제의 연구 및 개발에 주력하고 있습니다. 자세한 내용
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 AIM ImmunoTech 과거 주가 현재 주가 US$0.21 52주 최고치 US$0.60 52주 최저치 US$0.18 베타 -0.40 1개월 변경 -3.58% 3개월 변경 사항 -24.25% 1년 변경 사항 -51.86% 3년 변화 -77.74% 5년 변화 n/a IPO 이후 변화 -99.16%
최근 뉴스 및 업데이트
Less than half of directors are independent Dec 26 AIM ImmunoTech Receives Non-Compliance Letter from NYSE American
Ted Kellner Provides Information to the Shareholders Dec 17
Ted D. Kellner Files Definitive Proxy Statement with Securities and Exchange Commission Dec 11
AIM Immunotech Inc. Appoints William A. Carter as Chairman of Scientific Advisory Board Dec 10
Kellner Group Issues Press Release to Urge AIM Immunotech Stockholders to Vote the Gold Card Dec 03 더 많은 업데이트 보기
Less than half of directors are independent Dec 26 AIM ImmunoTech Receives Non-Compliance Letter from NYSE American
Ted Kellner Provides Information to the Shareholders Dec 17
Ted D. Kellner Files Definitive Proxy Statement with Securities and Exchange Commission Dec 11
AIM Immunotech Inc. Appoints William A. Carter as Chairman of Scientific Advisory Board Dec 10
Kellner Group Issues Press Release to Urge AIM Immunotech Stockholders to Vote the Gold Card Dec 03
New major risk - Revenue and earnings growth Nov 23
Third quarter 2024 earnings released: US$0.064 loss per share (vs US$0.16 loss in 3Q 2023) Nov 17
Kellner Group Urges Immediate Change at AIM Immunotech Inc Nov 15
AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024 Nov 06 AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024 Nov 05
AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million. Oct 02
AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million. Sep 30
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Sep 19
Ted D. Kellner Sends a Notice to AIM ImmunoTech Sep 04
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Aug 20
Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023) Aug 16
Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board Aug 15
AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy Jul 24 AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million. Jun 01
New major risk - Financial position May 17
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023) May 17
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Apr 10
New minor risk - Shareholder dilution Apr 08
Full year 2023 earnings released: US$0.60 loss per share (vs US$0.41 loss in FY 2022) Apr 03
AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024 Mar 27 AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding Feb 21
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions Feb 08
AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023 Nov 29
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions Nov 22
Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.13 loss in 3Q 2022) Nov 17
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen Nov 15
AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer Nov 09
AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023 Nov 08
AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023 Nov 07
Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation Aug 29
Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2022) Aug 16
AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions Aug 09
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions Jul 12
AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer Jun 28
AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments Jun 13
First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022) May 17
Insufficient new directors Mar 02
Insufficient new directors Feb 11
AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod) Jan 10
Executive Vice Chairman recently bought US$50k worth of stock Jan 06
Insufficient new directors Jan 04
AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer Dec 13
Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects Dec 10
Insufficient new directors Nov 22
AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen Nov 15
ASFV Committee Issues a Statement on Ruling in Delaware Action Nov 02
ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action Oct 25
Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech Oct 20
Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Oct 14
AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions Oct 13
Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech Sep 30
AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022 Sep 21
AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022 Sep 20 AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma
AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer Aug 19
Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation Aug 17
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID Jul 29
Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc Jul 23
Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc Jul 22
AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data Jul 21
Insufficient new directors Jun 22
AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program May 19
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies Apr 22
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer Apr 13
AIM ImmunoTech Inc. Announces Positive Data from Phase 1 Study Evaluating Ampligen Apr 12
Full year 2021 earnings released: US$0.40 loss per share (vs US$0.45 loss in FY 2020) Apr 02
Insufficient new directors Mar 09
AIM ImmunoTech Inc. Announces Executive Changes Mar 05
AIM ImmunoTech Inc. Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer Jan 25
Third quarter 2021 earnings released: US$0.08 loss per share (vs US$0.085 loss in 3Q 2020) Nov 19
Insufficient new directors Nov 17
Insufficient new directors Oct 27
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19 Sep 30
AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-Covid-19 Cognitive Dysfunction Sep 23
AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Trial Using its Drug Ampligen Sep 21
Insufficient new directors Sep 17
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction Sep 09 주주 수익률 0A4Y GB Biotechs GB 마켓 7D 8.5% 0.2% 0.8% 1Y -51.9% -26.1% 2.7%
전체 주주 수익률 보기
수익률 대 산업: 0A4Y 지난 1년 동안 -26.1 %를 반환한 UK Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 0A4Y 지난 1년 동안 2.7 %를 반환한 UK 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 0A4Y's price volatile compared to industry and market? 0A4Y volatility 0A4Y Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
안정적인 주가: 데이터를 사용할 수 없습니다.
시간에 따른 변동성: 지난 1년간 0A4Y 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
회사 소개 면역 제약 회사인 AIM ImmunoTech는 미국에서 여러 유형의 암, 바이러스 질환 및 면역 결핍 장애를 치료하는 치료제의 연구 및 개발에 주력하고 있습니다. 이 회사의 주요 제품 후보로는 만성피로증후군(CFS) 치료를 위한 고분자 리보핵산 약물인 앰플리젠이 있습니다. 또한 췌장암, 신세포암, 악성 흑색종, 비소세포폐암, 난소암, 유방암, 대장암, 전립선암, 근육성 뇌척수염, B형 간염, HIV, COVID-19 및 코로나 이후 질환 치료를 위한 앰플리젠을 개발 중입니다.
자세히 보기 AIM ImmunoTech Inc. 기본 사항 요약 AIM ImmunoTech 의 수익과 매출은 시가총액과 어떻게 비교하나요? 0A4Y 기본 통계 시가총액 US$13.29m 수익(TTM ) -US$23.93m 수익(TTM ) US$190.00k
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 0A4Y 손익 계산서(TTM ) 수익 US$190.00k 수익 비용 US$36.00k 총 이익 US$154.00k 기타 비용 US$24.08m 수익 -US$23.93m
주당 순이익(EPS) -0.38 총 마진 81.05% 순이익 마진 -12,594.21% 부채/자본 비율 93.8%
0A4Y 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/28 03:23 장 마감 주가 2024/12/27 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 AIM ImmunoTech Inc. 4 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Edward Woo Ascendiant Capital Markets LLC Ling Wang Chardan Capital Markets, LLC Jason McCarthy Maxim Group
1 더 많은 분석가 보기 
